Vesalius Longevity Labs Commences Trading Today on the Canadian Securities Exchange Under the Symbol "VLAB"

(CSE:VLAB) Vesalius Longevity Labs Inc. announced that it will commence trading on the Canadian Securities Exchange under the symbol 'VLAB' on November 12, 2026. Dr. Pradeep Albert, MD, CEO of Vesalius Labs, expressed gratitude to the Board of Directors, team, shareholders, and stakeholders for their support. Dr. Albert stated that Vesalius aims to become a leading global brand in longevity and wellness, emphasizing the company's focus on science and quality. Vesalius is positioning itself as one of the first publicly traded companies in the longevity sector. The company is building a comprehensive pathway from laboratory to consumer, including the production of Made-in-the-USA peptide APIs under the Peptual® brand. Vesalius operates a doctor-led model that connects licensed providers with patients. The company is also developing AI-powered tools to personalize care. Vesalius's business model includes a scalable B2Doctor2Consumer ecosystem to support healthcare providers and telehealth infrastructure. The company will manufacture peptide APIs for both domestic and international compounding supply chains under the Peptual® brand. Vesalius's ecosystem encompasses regenerative medicine, compounding pharmacy initiatives, biologics partnerships, and advanced AI-powered technologies. The company’s Listing Statement is dated November 9, 2026 and is available on SEDAR+ at www.sedarplus.ca. Vesalius is focused on being a trusted seed-to-brand partner for peptide therapeutics, biologics, and preventative healthcare. The company highlights its commitment to supporting the future of personalized health and wellness. No financial figures, production volumes, or contract values are disclosed in this announcement. The company encourages investors to visit its website for more information.